You are here
P&T January 2018
Will Medication Price Hikes Cool Down as a Result?
Is industry consolidation a response to President Donald Trump’s repeated denunciation of high drug prices and congressional hearings on the issue? The author considers whether any of this corporate collaboration will get at some of the significant, underlying problems in the drug-pricing space.
Health Care & Law
Despite the president’s urging, congressional efforts to repeal the Patient Protection and Affordable Care Act (PPACA) have been repeatedly unsuccessful. The authors explore key actions taken by the administration and department heads that have resulted in delayed enforcement of the PPACA and relaxation of the law.
With No Cure in Sight, Experts Urge Early Diagnosis and Prompt Treatment With Better Adherence
Although a significant increase in life expectancy for people with human immunodeficiency virus was reported last spring, experts in the U.S. caution that the results are not a cause for complacency. Efforts to develop a vaccine and a cure remain essential, as do efforts to develop interventions that may improve adherence.
We review key sessions from the 2017 AHA Scientific Sessions that included pharmacological aspects of treatment for peripheral artery disease, type-2 diabetes, percutaneous coronary intervention, atrial fibrillation, and hypertension.
Clinical Relevance and Cost-Savings of Levocarnitine Versus Ammonul in the Management Of Hyperammonemia in a Cancer Patient
The Impact of a Clinical Pharmacist
The authors present a case report illustrating how the role of a clinical pharmacist helped avert adverse consequences and promoted considerable cost-savings. This case also shows that levocarnitine may be an effective treatment for certain cases of hyperammonia-induced encephalopathy with unknown etiology.
Delayed Administration and Contraindicated Drugs Place Hospitalized Parkinson’s Disease Patients at Risk
Inpatients with Parkinson’s disease require precise medication management
CMS finalizes drastic 340B reimbursement cut for 2018
Approvals, new indications, regulatory activities, and more
Latanoprostene bunod ophthalmic solution (Vyzulta) for the reduction of intraocular pressure; letermovir (Prevymis) for prophylaxis of cytomegalovirus infection and disease after stem cell transplant; benralizumab (Fasenra) for the add-on maintenance treatment of severe asthma of an eosinophilic phenotype
Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis